Research Article
Identification of Differentially Expressed Kinase and Screening Potential Anticancer Drugs in Papillary Thyroid Carcinoma
Table 2
Potential novel kinase inhibitors for the treatment of PTC.
| | Kinase | Kinase inhibitor | Publication number |
| | EGFR | Gefitinib (ZD1839) | 3040 | | Erlotinib HCl (OSI-744) | 4310 | | Lapatinib | 1681 | | Afatinib (BIBW2992) | 409 | | AZD8931 (Sapitinib) | 389 | | AG-1478 (Tyrphostin AG-1478) | 273 | | AG-490 (Tyrphostin B42) | 221 | | PD153035 HCl | 136 | | Neratinib (HKI-272) | 113 | | Canertinib (CI-1033) | 94 | | Icotinib | 69 | | AEE788 (NVP-AEE788) | 61 | | Pelitinib (EKB-569) | 43 | | Varlitinib | 32 | | OSI-420 | 31 | | PD168393 | 24 | | Rociletinib (CO-1686, AVL-301) | 23 | | WZ4002 | 18 | | WHI-P154 | 15 | | CUDC-101 | 13 | | TAK-285 | 12 | | Tyrphostin 9 | 8 | | AST-1306 | 5 | | CL-387785 (EKI-785) | 5 | | AG-18 | 2 |
| | SRC | Dasatinib | 1771 | | PP2 | 345 | | Bosutinib (SKI-606) | 207 | | Saracatinib (AZD0530) | 126 | | SU6656 | 64 | | KX2-391 | 8 | | NVP-BHG712 | 2 | | Dasatinib Monohydrate | 2 |
| | MAPK | BMS-536924 | 29 |
| | MET | SU11274 | 98 | | Foretinib (GSK1363089) | 26 | | SGX-523 | 7 | | NPS-1034 | 2 | | NVP-BVU972 | 2 |
| | ATM | AZD8055 | 66 | | KU-55933 (ATM Kinase Inhibitor) | 42 | | KU-60019 | 9 |
| | CDK6 | Flavopiridol (Alvocidib) HCl | 374 | | PD-0332991 | 137 | | LY2835219 | 9 | | LDC000067 | 1 |
| | TGFbR1 | SB431542 | 114 | | SD-208 | 25 | | SB505124 | 10 | | EW-7197 | 8 | | SB525334 | 6 | | D 4476 | 2 | | RepSox | 1 | | GW788388 | 1 |
| | PDGFRa | Imatinib (STI571) | 6749 | | Ponatinib (AP24534) | 192 | | Nintedanib (BIBF 1120) | 102 | | Masitinib (AB1010) | 52 | | Lenvatinib (E7080) | 28 | | Quizartinib (AC220) | 24 | | Crenolanib (CP-868596) | 19 | | Amuvatinib (MP-470) | 13 | | ENMD-2076 | 12 | | Telatinib | 11 | | OSI-930 | 8 | | CP-673451 | 5 |
| | ErbB4 | AZD8931 (Sapitinib) | 12 |
|
|
